A new frontier in understanding the mechanisms of developmental abnormalities.

Recent advancements in molecular developmental biology afford an opportunity to apply newly developed tools for understanding the mechanisms of both normal and abnormal development. Although a number of agents have been identified as causing developmental abnormalities, our knowledge of the mechanisms by which these alterations occur is minimal. This paper reviews some of the important issues in this area that may lead to understanding the basic developmental processes and mechanisms by which toxic agents may interfere with these processes. Approximately 70% of developmental defects are of unknown etiology. Historically, it has been assumed that these defects were most likely to be induced by exposure to chemical or physical agents during organogenesis. There is now convincing evidence that exposure during preorganogenesis developmental stages to certain agents can also lead to fetal abnormalities as a result of direct damage to the exposed early conceptus. Thus, pre- or postimplantation exposure of the developing conceptus to toxicants may result in a "derailment" in the genetic control of development and the coordinated cascade of events that occur during normal development. For example, developmental abnormalities may be induced by disrupting the coordinated expression of developmental genes involved in genomic imprinting, cell lineage specification, cell mixing and recognition, cell-cell interaction, cell migration and differentiation, and segmentation, depending on the time of exposure. Because of our lack of knowledge about the molecular and cellular bases of chemically induced abnormal development, a number of assumptions are currently used in the process of evaluating and interpreting data for developmental toxicity studies. The study of mechanisms of normal and abnormal development and the pharmacokinetic-pharmacodynamic relationships in humans and experimental animals are key to the development of appropriate risk assessment assumptions and dose-response models for characterizing the risk for developmental toxicity in the human population. This article summarizes the discussions of the workshop on developmental abnormalities organized by the Committee on Toxicology of the National Research Council.

Evaluation of the mutagenic potential of corn (Zea mays L.) grown in untreated and atrazine (AAtrex) treated soil in the field.

Bacterial assays using extracts from field corn plants (harvested at one month, silage and mature stages) do not indicate that soil treatment with atrazine, at its maximum use rate, alters the endogenous mutagens present in these extracts, nor that atrazine itself is degraded to mutagenic products. Extracts of corn grown in soil treated with AAtrex were equally mutagenic with those of corn grown in untreated soil when tested in Salmonella typhimurium TA-100 by a reversion assay or in Salmonella typhimurium TM-677 in a forward mutation assay. Higher concentrations of histidine in corn grown in AAtrex treated soil may interfere with the reversion assay, but do not affect the forward mutation assay. The nature of the agent(s) responsible for the positive response was not determined. The mutagenicity may be due to natural plant constituents, an artifact of the sample preparation, or mycotoxins from some unrecognized plant infection. The experimental results in these field studies do not show that atrazine is degraded or metabolized by corn plants to mutagens in this sensitive bacterial assay.